MDxHealth S.A. (MDXH) Financial Ratios
21 years of historical data (2004–2024) · Healthcare · Medical - Diagnostics & Research
EV/EBITDA
N/A
—
5yr avg: N/A
P/FCF
N/A
—
5yr avg: N/A
P/B Ratio
↑
6.59
↓-26% vs avg
5yr avg: 8.92
30Y Low2.5·High14.2
ROE
↓
-345.3%
↑-27% vs avg
5yr avg: -271.6%
30Y Low-345%·High-26%
Debt/EBITDA
N/A
—
5yr avg: N/A
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
MDXH Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
MDxHealth S.A. currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $103M | $115M | $102M | $105M | $116M | — | — | — | — | — | — |
| Enterprise Value | $117M | $129M | $121M | $129M | $73M | — | — | — | — | — | — |
| P/E Ratio → | -1.73 | — | — | — | — | — | — | — | — | — | — |
| P/S Ratio | 1.15 | 1.28 | 1.45 | 2.83 | 5.22 | — | — | — | — | — | — |
| P/B Ratio | 6.59 | 7.77 | 14.16 | 11.26 | 2.48 | — | — | — | — | — | — |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
MDXH EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 1.43 | 1.72 | 3.49 | 3.29 | — | — | — | — | — | — |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — | — | — |
MDXH Profitability
Margins and return-on-capital ratios measuring operating efficiency
MDxHealth S.A. earns an operating margin of -27.5%. Operating margins have expanded from -102.3% to -27.5% over the past 3 years, signaling improving operational efficiency. A negative ROE of -345.3% indicates the company is currently destroying shareholder equity.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 61.2% | 61.2% | 62.6% | 51.9% | 47.5% | 43.6% | -1.2% | 58.9% | 74.8% | 66.2% | 60.5% |
| Operating Margin | -27.5% | -27.5% | -38.9% | -102.3% | -120.7% | -146.9% | -366.3% | -113.3% | -30.3% | -43.0% | -82.3% |
| Net Profit Margin | -42.3% | -42.3% | -61.4% | -118.9% | -130.4% | -155.3% | -365.7% | -114.5% | -30.3% | -44.1% | -82.9% |
Return on Capital
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -345.3% | -345.3% | -521.7% | -156.7% | -110.0% | -224.2% | -120.0% | -67.8% | -25.5% | -27.2% | -42.5% |
| ROA | -26.6% | -26.6% | -34.7% | -45.4% | -54.2% | -79.1% | -81.2% | -52.3% | -19.5% | -21.0% | -32.6% |
| ROIC | -68.4% | -68.4% | -68.7% | -151.3% | -414.0% | -281.7% | -184.4% | -89.1% | -36.5% | -51.6% | -110.8% |
| ROCE | -22.0% | -22.0% | -26.0% | -47.5% | -69.3% | -110.6% | -102.5% | -64.6% | -24.4% | -25.2% | -40.6% |
MDXH Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
Net debt stands at $13M ($60M total debt minus $47M cash).
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 4.05 | 4.05 | 5.72 | 4.27 | 0.33 | 2.71 | 0.56 | 0.01 | 0.02 | 0.01 | 0.02 |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | 0.89 | 2.62 | 2.61 | -0.92 | -0.01 | -0.56 | -0.49 | -0.37 | -0.57 | -0.67 |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — | — | — | — |
| Interest Coverage | -3.24 | -3.24 | -4.73 | -13.82 | -14.32 | -17.58 | -83.66 | -391.44 | -100.61 | — | -145.27 |
MDXH Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
A current ratio of 1.57x means MDxHealth S.A. can comfortably meet its short-term obligations, though there is limited excess liquidity.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 1.57 | 1.57 | 1.95 | 1.59 | 4.05 | 1.77 | 2.96 | 4.17 | 3.00 | 4.09 | 4.12 |
| Quick Ratio | 1.48 | 1.48 | 1.81 | 1.47 | 3.94 | 1.59 | 2.85 | 4.01 | 2.85 | 3.97 | 3.99 |
| Cash Ratio | 1.10 | 1.10 | 1.15 | 0.85 | 3.57 | 1.23 | 2.12 | 2.28 | 1.28 | 2.42 | 2.82 |
| Asset Turnover | — | 0.57 | 0.54 | 0.31 | 0.30 | 0.58 | 0.29 | 0.43 | 0.69 | 0.44 | 0.30 |
| Inventory Turnover | 9.02 | 9.02 | 9.45 | 7.66 | 6.11 | 4.48 | 10.01 | 6.45 | 5.32 | 6.83 | 4.84 |
| Days Sales Outstanding | — | 58.90 | 58.61 | 92.17 | 75.20 | 76.99 | 205.81 | 246.42 | 179.59 | 226.51 | 234.17 |
MDXH Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
MDxHealth S.A. does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — | — | — | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — | — | — | — | — |
| Shares Outstanding | — | $49M | $26M | $16M | $12M | $8M | $6M | $6M | $5M | $5M | $4M |
Peer Comparison
Compare MDXH with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 MDXHYou | $103M | -1.7 | — | — | 61.2% | -27.5% | -345.3% | -68.4% | — |
 EXAS | $20B | -95.4 | — | 56.1 | 69.7% | -6.4% | -8.7% | -3.6% | — |
 VCYT | $3B | 49.7 | 30.7 | 25.7 | 69.6% | 14.3% | 5.3% | 5.6% | 0.4 |
 NTRA | $31B | -144.6 | — | 285.5 | 64.8% | -13.4% | -14.3% | -36.1% | — |
 QDEL | $733M | -0.6 | — | — | 46.7% | -33.7% | -46.1% | -13.6% | — |
 ILMN | $21B | 25.5 | 19.6 | 22.6 | 66.7% | 19.9% | 33.4% | 16.8% | 2.3 |
 PACB | $498M | -0.9 | — | — | 31.7% | -348.5% | -213.5% | -45.8% | — |
 CDNA | $1B | -53.6 | — | 30.7 | 67.0% | -5.5% | -6.3% | -5.7% | — |
 PRME | $562M | -2.3 | — | — | -58.1% | -4498.1% | -146.8% | -168.3% | — |
 LH | $21B | 24.7 | 12.7 | 17.6 | 26.8% | 10.9% | 10.5% | 7.8% | 3.3 |
 DGX | $21B | 21.8 | 12.7 | 15.5 | 31.9% | 14.5% | 14.0% | 8.8% | 3.2 |
| Healthcare Median | — | 22.3 | 14.4 | 18.5 | 63.9% | -5.2% | -33.7% | -11.2% | 3.3 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 21 years · Updated daily
See MDXH's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs MDXH Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare MDXH vs EXAS
Side-by-side business, growth, and profitability comparison vs Exact Sciences Corporation.
Start ComparisonMDXH — Frequently Asked Questions
Quick answers to the most common questions about buying MDXH stock.
What is MDxHealth S.A.'s P/E ratio?
MDxHealth S.A.'s current P/E ratio is -1.7x. This places it at the 50th percentile of its historical range.
What is MDxHealth S.A.'s ROE?
MDxHealth S.A.'s return on equity (ROE) is -345.3%. The historical average is -88.1%.
Is MDXH stock overvalued?
Based on historical data, MDxHealth S.A. is trading at a P/E of -1.7x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
What are MDxHealth S.A.'s profit margins?
MDxHealth S.A. has 61.2% gross margin and -27.5% operating margin.